Dr. Girish Dhall, MD
Claim this profileChildren's Hospital of Alabama
About Girish Dhall, MD
Education:
- Obtained MD from the University of Alabama at Birmingham School of Medicine in 2006.
- Completed Residency in Pediatrics at the University of Alabama at Birmingham in 2009.
- Finished Fellowship in Pediatric Hematology/Oncology at the University of Alabama at Birmingham in 2012.
Experience:
- Associate Professor of Pediatrics and Director of the Neuro-Oncology Program at the Children's Hospital of Alabama.
Area of expertise
Brain Cancer
Girish Dhall, MD has run 8 trials for Brain Cancer. Some of their research focus areas include:
Brain Tumor
Girish Dhall, MD has run 6 trials for Brain Tumor. Some of their research focus areas include:
Affiliated Hospitals
Children's Hospital Of Alabama
University Of Alabama At Birmingham
Clinical Trials Girish Dhall, MD is currently running
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting
1 award
Phase 1 & 2
13 criteria
Sodium Thiosulfate
for Hearing Loss in Medulloblastoma
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effective at treating the cancer, there are still concerns about the side effects of such treatment. Side effects or unintended health conditions that arise due to treatment include learning difficulties, hearing loss or other issues in performing daily activities. Standard therapy for newly diagnosed average-risk or low-risk medulloblastoma includes surgery, radiation therapy, and chemotherapy (including cisplatin). Cisplatin may cause hearing loss as a side effect. In the average-risk medulloblastoma patients, this trial tests whether the addition of sodium thiosulfate (STS) to standard of care chemotherapy and radiation therapy reduces hearing loss. Previous studies with STS have shown that it may help reduce or prevent hearing loss caused by cisplatin. In the low-risk medulloblastoma patients, the study tests whether a less intense therapy (reduced radiation) can provide the same benefits as the more intense therapy. The less intense therapy may cause fewer side effects. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. The overall goals of this study are to see if giving STS along with standard treatment (radiation therapy and chemotherapy) will reduce hearing loss in medulloblastoma patients and to compare the overall outcome of patients with medulloblastoma treated with STS to patients treated without STS on a previous study in order to make sure that survival and recurrence of tumor is not worsened.
Recruiting
3 awards
Phase 3
More about Girish Dhall, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 9 Active Clinical Trials
Treatments Girish Dhall, MD has experience with
- Radiation Therapy
- Vincristine
- Nivolumab
- Cyclophosphamide
- Lomustine
- Fludarabine
Breakdown of trials Girish Dhall, MD has run
Brain Cancer
Brain Tumor
Diffuse Hemispheric Glioma
Malignant Glioma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Girish Dhall, MD specialize in?
Girish Dhall, MD focuses on Brain Cancer and Brain Tumor. In particular, much of their work with Brain Cancer has involved Stage I patients, or patients who are Stage II.
Is Girish Dhall, MD currently recruiting for clinical trials?
Yes, Girish Dhall, MD is currently recruiting for 9 clinical trials in Birmingham Alabama. If you're interested in participating, you should apply.
Are there any treatments that Girish Dhall, MD has studied deeply?
Yes, Girish Dhall, MD has studied treatments such as Radiation Therapy, Vincristine, Nivolumab.
What is the best way to schedule an appointment with Girish Dhall, MD?
Apply for one of the trials that Girish Dhall, MD is conducting.
What is the office address of Girish Dhall, MD?
The office of Girish Dhall, MD is located at: Children's Hospital of Alabama, Birmingham, Alabama 35233 United States. This is the address for their practice at the Children's Hospital of Alabama.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.